ArticleFrontiers in microbiology2026
Clinical evaluation of EUCAST rapid antimicrobial susceptibility testing in Gram-negative bacilli bloodstream infections: a real-world retrospective study.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objectives: Rapid antimicrobial susceptibility testing (RAST) performed directly from positive blood cultures may facilitate earlier optimization of antimicrobial therapy in bloodstream infections. In this single-center retrospective study, we evaluated the clinical performance of the EUCAST RAST method for Gram-negative bacilli bloodstream infections (GNB BSIs) by assessing its agreement with routine susceptibility testing, its potential to support earlier antimicrobial modification, and its effect on turnaround time (TAT) for susceptibility reporting. Methods: A total of 229 patients with Gram-negative bacilli detected in positive blood cultures were collected from November 2025 to March 2026. EUCAST RAST was performed directly from positive blood cultures in parallel with the standard antimicrobial susceptibility testing workflow. RAST categorical agreement (CA) with the comparator method, interpretability of results, potential antibiotic modifications based on RAST, and TAT for susceptibility reporting were evaluated. Results: A total of 187 isolates (81.7%) met the predefined inclusion criteria and were subsequently included in the final analysis. According to the BD Phoenix M50 system, 1.1% of isolates were carbapenem-resistant and 34.3% were extended-spectrum β-lactamase producers. The overall categorical agreement of RAST for all tested antibiotics was 99.4% at 6 h and 100.0% at 16-20 h, with 70% of results interpretable at 6 h. RAST results supported potential antimicrobial modification in 32.1% of patients, including de-escalation in 7.5% and escalation in 24.6%. Among 16 patients receiving ineffective empirical therapy, 13 (81.3%) could potentially have been switched earlier to active treatment based on RAST results. The median TAT for susceptibility reporting decreased from 44 h (IQR, 39.5-47.0) to 26 h (IQR, 21.5-29.0) compared with short-term methods and from 61.5 h (IQR, 58.0-67.0) to 37.5 h (IQR, 35.0-42.0) compared with conventional methods. The overall mortality rate was only 10.7%. Conclusion: European Committee on Antimicrobial Susceptibility Testing RAST provided reliable early susceptibility results for Gram-negative bacilli directly from positive blood cultures and substantially shortened reporting time, supporting earlier antimicrobial optimization and antimicrobial stewardship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.